Pfizer Inc. is in advanced talks to buy Global Blood Therapeutics Inc., the maker of a sickle cell treatment, for about $5 billion, the the wall street journal reported.
The Midtown-based drug giant is looking to finalize a deal in the coming days, the Journal reported, citing people familiar with the matter who asked not to be identified. Bloomberg News reported earlier this week that biotech is attracting interest from big pharma.
Shares of Global Blood gained as much as 52% on Friday in New York after being briefly halted for volatility. Shares of Bluebird Bio Inc., which is developing sickle cell therapy, gained 16% at 12:52 p.m. Pfizer fell 0.9%.